Understanding the anti-tumour immune response to radionuclide therapy using PSMA targeting radiopharmaceuticals in a prostate cancer model
<p>The ability of external beam radiation (EBRT) to modulate the tumour immune microenvironment is becoming increasingly well understood, leading to the development of combinatorial EBRT and immunotherapeutic combinations to improve patient responses. Despite this, there is very limited unders...
Autore principale: | Anderson, R |
---|---|
Altri autori: | Vallis, K |
Natura: | Tesi |
Lingua: | English |
Pubblicazione: |
2021
|
Soggetti: |
Documenti analoghi
-
Recent Progress of Functionalized PSMA in Radionuclide Targeted Therapy for Prostate Cancer
di: REN Ya'nan, et al.
Pubblicazione: (2020-12-01) -
Lead-212 Radiopharmaceuticals for Receptor-Targeted Radionuclide Therapy
di: Solmaz Mojarad-Jabali, et al.
Pubblicazione: (2025-01-01) -
Radiopharmaceuticals: From Molecular Imaging to Targeted Radionuclide Therapy
di: P. August Schubiger, et al.
Pubblicazione: (2004-10-01) -
Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
di: Paweł Szponar, et al.
Pubblicazione: (2023-11-01) -
Can PSMA-Targeting Radiopharmaceuticals Be Useful for Detecting Hepatocellular Carcinoma Using Positron Emission Tomography? An Updated Systematic Review and Meta-Analysis
di: Alessio Rizzo, et al.
Pubblicazione: (2022-11-01)